Categories
BRI Executive Committee Education

Paul Anderson, MD, PhD

He is the K. Frank Austen Professor of Medicine at Harvard Medical School and the associate chief of the Division of Rheumatology, Inflammation, and Immunity at Brigham and Women’s Hospital.

He is a member of the American Society for Clinical Investigation and the Association of American Physicians and serves on the Scientific Advisory Committee at the American College of Rheumatology. Before graduating from the medical scientist training program at the New York University School of Medicine, Anderson trained with Jan Vilcek, MD, PhD, the inventor of Remicaid, the first biologic therapy for patients with autoimmune disease. Anderson then came to the Brigham where he completed an internship and residency in Internal Medicine and a fellowship in Rheumatology. In 1990 he started his own research laboratory at the Brigham focusing on the role that post-transcriptional control of gene expression plays in the regulation of inflammatory and stress response programs. His laboratory has been funded by the NIH and by various foundations and industry collaborations, and has hosted more than 30 MD and/or PhD research fellows.

He has authored or co-authored more than 175 publications and is on the editorial boards of a number of journals, including Cellular Immunology and Modern Rheumatology. In addition, Anderson is a senior physician at the Brigham and sees patients in the Brigham arthritis ambulatory clinic and attends on the Rheumatology consult service. He is a member of the Rheumatology Division Fellowship Selection Committee, which interviews all applicants for the Rheumatology Fellowship Program and makes recommendations for ranking these candidates.

Anderson received a BS in Biology from SUNY Stony Brook, and received both MD and PhD (Microbiology) from New York University School of Medicine.

Categories
News

Q&A with Paul Anderson, MD, PhD: Research and Innovation in the Time of COVID-19

Clinical and Research News (CRN) recently published a Q&A with Paul Anderson:

“In March, research leadership made an unprecedented decision. To help reduce the spread of COVID-19, the Brigham shut down the majority of its physical research labs. But that hasn’t stopped research teams from innovating. Labs that can do so are performing their work remotely, and labs that are performing essential functions, including COVID-19 research, are continuing their critical work on site.

Paul Anderson, MD, PhD, Senior Vice President of Research and Education, Chief Academic Office for the Brigham

Paul Anderson, MD, PhD, senior vice president of research and education and chief academic officer for the Brigham, recently answered questions about the laboratory shutdown, the launch of the Center for COVID Innovation and his hopes for the future.

In addition, the Brigham and Mass General research communities have come together to launch the Mass General Brigham Center for COVID Innovation (MGBCCI).

Paul Anderson, MD, PhD

Read the full conversation in Clinical and Research News here.